No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ALGS Aligos Therapeutics
- 0.528
- +0.024+4.82%
Trading Jul 22 15:00 ET
41.24MMarket Cap-502P/E (TTM)
0.567High0.501Low319.72KVolume0.515Open0.504Pre Close169.97KTurnover0.80%Turnover RatioLossP/E (Static)78.11MShares1.20052wk High0.69P/B21.23MFloat Cap0.34852wk Low--Dividend TTM40.22MShs Float37.510Historical High--Div YieldTTM13.12%Amplitude0.348Historical Low0.531Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Aligos Therapeutics And Amoytop To Sponsor Phase 1b Study Evaluating Efficacy And Safety Of ALG-000184 With PEGBING In CHB Patients
Express News | Aligos Therapeutics Inc: Clinical Study Is Expected to Begin After Approval by National Medical Products Administration in China
Express News | Aligos Therapeutics: Amoytop to Sponsor, Perform Phase 1B Study Evaluating Efficacy, Safety of Alg-000184 in Combination With Pegbing
Express News | Aligos Therapeutics Announces Clinical Collaboration With Xiamen Amoytop Biotech Co., Ltd.
Aligos Therapeutics (ALGS) Receives a Buy From Piper Sandler
Benign Growth For Aligos Therapeutics, Inc. (NASDAQ:ALGS) Underpins Stock's 26% Plummet
To the annoyance of some shareholders, Aligos Therapeutics, Inc. (NASDAQ:ALGS) shares are down a considerable 26% in the last month, which continues a horrid run for the company. The recent drop co
Comments
$Aligos Therapeutics(ALGS.US$
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
Aligos Therapeutics (Nasdaq: ALGS) has announced a clinical trial collaboration with Xiamen Amoytop Biotech to evaluate the combination of ALG-000184 and PEGBING® (Mipeginterferon alfa-2b) in chronic hepatitis B (CHB) patients in China. Amoytop will sponsor a Phase 1b exploratory study to assess the efficacy and safety of this combination.
ALG-000184 is a potent oral cap...
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
Aligos Therapeutics (Nasdaq: ALGS) has announced a clinical trial collaboration with Xiamen Amoytop Biotech to evaluate the combination of ALG-000184 and PEGBING® (Mipeginterferon alfa-2b) in chronic hepatitis B (CHB) patients in China. Amoytop will sponsor a Phase 1b exploratory study to assess the efficacy and safety of this combination.
ALG-000184 is a potent oral cap...
$Aligos Therapeutics(ALGS.US$
NEWS
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
Aligos Therapeutics (Nasdaq: ALGS) has completed enrollment for its Phase 2a HERALD study of ALG-055009, targeting metabolic dysfunction-associated steatohepatitis (MASH). The study enrolled around 100 subjects with liver fibrosis. Topline safety and efficacy data are expected in early Q4 2024.
Dr. Rohit Loomba, a renowned expert in gast...
NEWS
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
Aligos Therapeutics (Nasdaq: ALGS) has completed enrollment for its Phase 2a HERALD study of ALG-055009, targeting metabolic dysfunction-associated steatohepatitis (MASH). The study enrolled around 100 subjects with liver fibrosis. Topline safety and efficacy data are expected in early Q4 2024.
Dr. Rohit Loomba, a renowned expert in gast...
1
$Aligos Therapeutics(ALGS.US$ Aligos Therapeutics Presents Positive Clinical Data at Escmid 2024 From the Alg-097558 Phase 1 Study
$Aligos Therapeutics(ALGS.US$
NEWS
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
The data shows that the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting.
The PK profile supports twice daily ritonavir-free dosing without a food effect.
Aligos has developed a robust clinical pipeline of three potentially best-in-class drug candidates.
The presentation highlights the best-in-class potent...
NEWS
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
The data shows that the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting.
The PK profile supports twice daily ritonavir-free dosing without a food effect.
Aligos has developed a robust clinical pipeline of three potentially best-in-class drug candidates.
The presentation highlights the best-in-class potent...
1
1
$Aligos Therapeutics(ALGS.US$ Mirum’s LIVMARLI receives positive reimbursement recommendation by Canada’s CADTH
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg